SWOG clinical trial number
SWOG-9501
A Phase II Trial of Fludarabine and Mitoxantrone (FN) for Treatment of Non-Hodgkin's Lymphoma
Closed
Phase
Accrual
100%
Published
Abbreviated Title
A Phase II Trial of Fludarabine and Mitoxantrone (FN) for Treatment of Non-Hodgkin's Lymphoma
Activated
04/01/1995
Closed
02/15/1996
Research committees
Lymphoma
Publication Information Expand/Collapse
2003
Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501
1999
SWOG 95-01: A phase II trial of a combination of fludarabine and mitoxantrone (FN) in untreated advanced low grade lymphoma. An effective, well tolerated therapy.
Other Clinical Trials
SWOG Clinical Trial Number
S2207
Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
6%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase
SWOG Clinical Trial Number
S2114
A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
02/23/2023
Accrual
11%
Open
Phase